Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this post-marketing surveillance study is to collect and assess information
retrospectively on safety and effectiveness of fondaparinux injection in patients with venous
thromboembolism (VTE) whose body weight is 100 kilograms (kg) or more, or to whom
fondaparinux was injected 10 mg/day.
("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)